Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 9.

Sudano, I; Hermann, M; Ruschitzka, F T (2007). Endothelin-receptor antagonists in arterial hypertension: further indications? Curr Hypertens Rep, 9(1):59-65.

Hermann, M; Enseleit, F; Ruschitzka, F T (2005). Anti-inflammatory strategies in hypertension: focus on COX-1 and COX-2. Current Hypertension Reports, 7(1):52-60.

Ruschitzka, F T (2005). Clinical trials report. The APPROVe study: what we should learn from the VIOXX withdrawal. Current Hypertension Reports, 7(1):41-43.

Hermann, F; Ruschitzka, F T; Schiffrin, E L (2004). Clinical trials report. CHARM-Alternative Trial. Current Hypertension Reports, 6(1):47.

Hermann, F; Ruschitzka, F T; Schiffrin, E L (2004). Clinical trials report. CHARM-Overall Programme. Current Hypertension Reports, 6(1):46.

Hermann, F; Ruschitzka, F T; Schiffrin, E L (2004). Clinical trials report. CHARM-Preserved Trial. Current Hypertension Reports, 6(1):48-50.

Hermann, F; Ruschitzka, F T; Schiffrin, E L (2004). Clinical trials report. The sweet secret of dark chocolate. Current Hypertension Reports, 6(1):45-46.

Ruschitzka, F T (2003). Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Current Hypertension Reports, 5(1):57-58.

Ruschitzka, F T; Wenger, R H; Stallmach, T; Quaschning, T; de Wit, C; Wagner, K; Labugger, R; Kelm, M; Noll, G; Rülicke, T; Shaw, S; Lindberg, R L; Rodenwaldt, B; Lutz, H; Bauer, C; Lüscher, T F; Gassmann, M (2000). Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 97(21):11609-11613.

This list was generated on Tue Nov 21 23:14:27 2017 CET.